Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Cancer: Breakthrough Pain × Ketamine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pain 5 Neoplasms 5 Pain, Intractable 3 Agnosia 2 Waldenstrom Macroglobulinemia 1 Thrombocythemia, Essential 1 Sezary Syndrome 1 Primary Myelofibrosis 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycythemia Vera 1 Peripheral Nervous System Diseases 1 Pdgfra-Associated Chronic Eosinophilic Leukemia 1 Pain, Procedural 1 Neurotoxicity Syndromes 1 Myeloproliferative Disorders 1 Mycosis Fungoides 1 Multiple Myeloma 1 Mucositis 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, Extranodal NK-T-Cell 1 Lymphoma, B-Cell, Marginal Zone 1 Leukemia, Prolymphocytic 1 Leukemia, Neutrophilic, Chronic 1

Interventions

Morphine 1 Ketamine 1 Chitosan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02591017 2018-11-13

ONKEMI

University Hospital, Basel, Switzerland

Phase 3 Terminated

Cancer: Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon ⚡